Savara, Inc. (SVRA) Stock Analysis

Q: What is the SVRA stock price target?

Take-profit $9.41 (+82.5% upside). Prior stop was $4.79.

Q: Is SVRA overvalued or undervalued?

Savara, Inc. trades at a P/E of N/A (forward -16.1). TrendMatrix value score: 9.0/10. Overall verdict: Sell.

Q: What do analysts say about SVRA?

14 analysts cover SVRA with a consensus score of 4.3/5. Average price target: $11.

SellVALUE-TRAP 1/5Moderate ConfidenceUpdated 2026-05-02

Healthcare · Biotechnology

$5.16+82.5% A.UpsideScore 4.9/10#96 of 158 Biotechnology

Stop $4.79Target $9.41(analyst − 13%)A.R:R 7.4:1

Analyst target$10.81+109.5%8 analysts

$9.41our TP

$5.16price

$10.81mean

$16

Sell if holding. Engine safety override at $5.16: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 7.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.9/10, moderate confidence.

Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Quality below floor (1.6 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-16.1

Mkt Cap$1.1B

EV/EBITDA-9.1

Profit Mgn0.0%

ROE-63.4%

Rev Growth—

Beta0.31

DividendNone

Rating analysts14

Quality Signals

Piotroski F4/9

Options Flow

P/C1.00neutral

IV53%elevated

Max Pain$10+93.8% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

4 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value9.015%1.35

Quality1.615%0.24

Growth5.015%0.75

Momentum3.210%0.32

Sentiment7.810%0.78

Insider Activity5.010%0.50

Peer Rank2.710%0.27

Technical Setup6.55%0.33

Risk Profile4.95%0.25

Catalyst2.55%0.13

Overall (Σ contributions)4.91

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Gross Margin

0.0

Operating Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Piotroski F

4.4

Current Ratio

5.0

Moat

5.0

Cash-burning (FCF negative)No competitive moatQuality concerns

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History

0.0

Surprise Avg

0.0

Erm

5.0

Earnings Timing

5.0

Earnings concerns: 1B/3MEarnings in 12 days

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank

1.0

Value Rank

5.0

Growth Rank

5.0

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Volume

0.0

Obv

1.0

Macd

3.0

Ma Position

4.0

Rsi

8.0

Uptrend pullback (RSI 35) - buy opportunityVolume distribution (falling OBV)Above 200-day MA

GatesMomentum 3.2<4.5EARNINGS PROXIMITY 12d<=14d (soft)A.R:R 7.4 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARSuitability: Aggressive

RSI

35 · Neutral

↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $4.83Resistance $6.24

Price Targets

A.Upside+82.4%

A.R:R7.4:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (1.6 < 4.0)

! Momentum score 3.2/10 — below 4.5 minimum

Earnings

1/4 beats

Next Earnings2026-05-13 (12d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is SVRA stock a buy right now?

Sell if holding. Engine safety override at $5.16: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 7.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $4.79. Score 4.9/10, moderate confidence.

What is the SVRA stock price target?

Take-profit target: $9.41 (+82.5% upside). Prior stop was $4.79. Stop-loss: $4.79.

What are the risks of investing in SVRA?

Quality below floor (1.6 < 4.0).

Is SVRA overvalued or undervalued?

Savara, Inc. trades at a P/E of N/A (forward -16.1). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about SVRA?

14 analysts cover SVRA with a consensus score of 4.3/5. Average price target: $11.

What does Savara, Inc. do?Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The...

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.